

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: CNSR-07141

Serial No.: 10/697,497

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)Applicant: Len Brandt *et al.*

Filing Date: 10/30/03

Group Art Unit: 1614

(37 CFR § 1.98(b))

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
✓	1	3,819,706	06/25/74	Mehta	260	570.5	11/30/70
✓	2	3,885,046	05/20/75	Mehta	424	330	08/23/73
✓	3	5,512,593	04/30/96	Dante	514	410	03/02/93
✓	4	5,817,665	10/06/98	Dante	514	282	11/20/95
✓	5	6,034,091	03/07/00	Dante	514	282	10/02/98
✓	6	6,080,736	06/27/00	Landry <i>et al.</i>	514	221	10/27/99
✓	7	6,228,875	05/08/01	Tsai	514	380	04/14/99
✓	8	6,239,162	05/29/01	Oxenkrug	514	415	04/27/00
✓	9	6,395,752	05/28/02	Midha <i>et al.</i>	514	317	08/11/00
✓	10	5,731,000	03/24/98	Ruff <i>et al.</i>	424	451	03/22/96
✓	11	5,968,553	10/19/99	Maitra <i>et al.</i>	424	474	12/30/97
✓	12	6,242,496	06/05/01	Kulkarni <i>et al.</i>	514	649	09/28/99
✓	13	6,333,332	12/25/01	Han <i>et al.</i>	514	276	08/25/00
✓	14	6,306,436	10/23/01	Chungi <i>et al.</i>	424	464	04/28/00
✓	15	6,369,113	04/09/02	Young	514	649	06/27/01
✓	16	6,150,420	11/21/00	Houdi <i>et al.</i>	514	649	01/22/99
✓	17	6,294,192	09/25/01	Patel <i>et al.</i>	424	451	02/26/99
✓	18	RE33,994	06/14/92	Baker <i>et al.</i>	424	465	08/04/89
✓	19	6,372,252	04/16/02	Blume <i>et al.</i>	424	464	04/28/00
✓	20	6,207,190	03/27/01	Richardson <i>et al.</i>	424	472	08/11/99
✓	21	6,319,519	11/20/01	Woolfe <i>et al.</i>	424	472	02/20/01
✓	22	6,287,600	09/11/01	Ouali <i>et al.</i>	424	472	03/20/00
✓	23	6,284,274	09/04/01	Merrill <i>et al.</i>	424	472	03/03/00
✓	24	6,258,816	07/10/01	Singh <i>et al.</i>	514	255	10/26/98
✓	25	6,087,386	07/11/00	Chen <i>et al.</i>	514	381	06/17/97
✓	26	5,620,705	04/15/97	Dong <i>et al.</i>	424	472	05/16/95
✓	27	5,879,701	03/09/99	Audett <i>et al.</i>	424	448	02/28/97
✓	28	4,638,043	01/20/87	Szycher <i>et al.</i>	528	75	08/23/85
✓	29	5,830,505	11/03/98	Fischer <i>et al.</i>	424	487	01/01/97
✓	30	5,840,327	11/24/98	Gale <i>et al.</i>	424	448	08/15/96
✓	31	6,197,827	03/06/01	Cary	514	646	11/16/99
✓	32	6,280,763	08/28/01	Midha <i>et al.</i>	424	448	05/10/99
✓	33	5,834,011	11/10/98	Rose <i>et al.</i>	424	449	06/07/98
✓	34	5,876,746	03/02/99	Jona <i>et al.</i>	424	449	06/06/96
✓	35	5,891,461	04/06/99	Jona <i>et al.</i>	424	449	09/14/95

Examiner:

Date Considered:

3/9/06

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: CNSR-07141	Serial No.: 10/697,497	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: Len Brandt <i>et al.</i>		
(37 CFR § 1.98(b))				Filing Date: 10/30/03	Group Art Unit: 1614	

U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
7	36	Des. 358,762	05/30/95	Walchek <i>et al.</i>	D9	341	10/20/93
	37	4,165,709	08/28/79	Studer	116	308	01/24/78
	38	6,138,866	10/31/2000	Lambelet <i>et al.</i>	221	25	09/09/99
	39	6,375,979	04/23/02	DiSanto <i>et al.</i>	424	449	03/05/01
	40	4,931,279	06/05/90	Bawa <i>et al.</i>	424	427	07/21/88
	41	4,668,506	05/26/87	Bawa <i>et al.</i>	424	429	08/16/85
	42	5,174,471	12/29/92	Kozlowski <i>et al.</i>	221	154	06/10/92
	43	5,351,858	10/04/94	Bar-Yona <i>et al.</i>	221	266	11/23/92
	44	4,736,849	04/12/88	Leonard <i>et al.</i>	206	534	08/12/85
	45	Des. 335,081	04/27/93	Pierantozzi <i>et al.</i>	D9	341	07/30/91
	46	5,145,682	09/08/92	Chien <i>et al.</i>	424	448	03/08/89
	47	3,651,927	03/28/72	Richardson <i>et al.</i>	206	42	10/21/69
	48	5,770,226	06/23/98	Hughes <i>et al.</i>	424	464	06/10/96
	49	4,807,757	02/28/89	Rappaport <i>et al.</i>	206	535	08/04/87
	50	3,678,884	07/25/72	Robbins	116	121	12/28/70
	51	4,640,560	02/03/87	Blum	312	234.1	12/17/84
	52	6,169,707	01/02/01	Newland	368	10	11/30/98

U.S. APPLICATION DOCUMENTS						
Cite No.	Serial No.	Applicant / Patentee	Class	Subclass	Filing Date	
53	2002/0035145	Tsai	514	472	04/13/01	
54	2002/0052341	Fang <i>et al.</i>	514	58	11/16/01	

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)	
55	Baldessarini, "Drugs and Treatment Of Psychiatric Disorders", In: Goodman and Gilman's The Pharmacological Basis Of Therapeutics, Eighth Edition, Goodman <i>et al.</i> , Eds, Pergamon Press, New York, Ch 18 pp.383-419 (1990)
56	Stoudemire A., "Expanding Psychopharmacologic Treatment Options For The Depressed Medical Patient", <i>Psychosomatics</i> , 36(2):S19-S26 (1995).
57	Andrews <i>et al.</i> , "Contemporary Management Of Depression", <i>Am J Med</i> 97(6A):24S-32S (1994)
58	Baumann P., "Pharmacokinetic-Pharmacodynamic Relationship Of The Selective Serotonin Reuptake Inhibitors", <i>Clin Pharmacokinet</i> , 31(6):444-69 (1996)
59	Mischoulon <i>et al.</i> , "Strategies For Managing Depression Refractory To Selective Serotonin Reuptake Inhibitor Treatment: A Survey Of Clinicians", <i>Can J Psychiatry</i> 45(5):476-81 (2000)
60	Katona C.L., "Refractory Depression: A Review With Particular Reference To The Use Of Lithium Augmentation", <i>Eur Neuropsychopharmacol Suppl</i> :109-113 (1995)
61	Appelberg <i>et al.</i> , "Patients With Severe Depression May Benefit From Buspirone Augmentation Of Selective Serotonin Reuptake Inhibitors: Results From A Placebo-Controlled, Randomized, Double-Blind, Placebo Wash-In Study", <i>J. Clin Psychiatry</i> , 62(6):448-452 (2001)
62	Shelton <i>et al.</i> , "A Novel Augmentation Strategy For Treating Resistant Major Depression", <i>Am J Psychiatry</i> 158:131-134 (2001)
63	Taylor D., "Selective Serotonin Reuptake Inhibitors And Tricyclic Antidepressants In Combination: Interactions And Therapeutic Uses", <i>Br J Psychiatry</i> 167:575-580 (1995).

Examiner:	Date Considered: 8/9/06
-----------	-------------------------

EXAMINER:	Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
-----------	---

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: CNSR-07141	Serial No.: 10/697,497
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: Len Brandt <i>et al.</i>	
(37 CFR § 1.98(b))				Filing Date: 10/30/03	Group Art Unit: 1614
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
7	64	Shelton R.C., "Treatment Options For Refractory Depression", <i>J Clin Psychiatry</i> 60 Suppl 4:57-61 (1999)			
	65	Doraiswamy <i>et al.</i> , "Quality Of Life In Geriatric Depression: A Comparison Of Remitters, Partial Responders, And Nonresponders", <i>Am J Geriatr Psychiatry</i> , 9(4):423-428 (2001)			
	66	Katz S.E., "Bupropion Treatment Of Refractory Depression", <i>J Clin Psychiatry</i> , 7:51-52 (1987).			
	67	Horst <i>et al.</i> , "Mechanisms of Action And Clinical Characteristics Of Three Atypical Antidepressants: Venlafaxine, Nefazodone, Bupropion", <i>J Affect Disord</i> 51(3):237-254 (1998)			
	68	Bryant <i>et al.</i> , "Review Of Bupropion", <i>Clin Pharm</i> , 2(6):525-537 (1983)			
	69	Rotzinger <i>et al.</i> , "Metabolism Of Some "Second"-And "Fourth"-Generation Antidepressants: Iprindole, Viloxazine, Bupropion, Mianserin, Maprotiline, Trazodone, Nefazodone, and Venlafaxine", <i>Cell Mol Neurobiol</i> , 19(4):427-442 (1999)			
	70	Preskorn <i>et al.</i> , "Evaluation Of Bupropion Hydrochloride: The First Of A New Class Of Atypical Antidepressants", <i>Pharmacotherapy</i> , 4(1):20-34 (1984)			
	71	Goodnick P.J., "Pharmacokinetics Of Second Generation Antidepressants: Bupropion", <i>Psychopharmacol Bull</i> 27(4):513-519 (1991).			
	72	Ascher <i>et al.</i> , "Bupropion: A Review Of Its Mechanism Of Antidepressant Activity", <i>J Clin Psychiatry</i> , 56(9):395-401 (1995)			
	73	Erfurth <i>et al.</i> , "Bupropion As Add-On Strategy In Difficult-To-Treat Bipolar Depressive Patients", <i>Neuropsychobiology</i> , 45 Suppl 1:33-36 (2002)			
	74	James <i>et al.</i> , "Bupropion: Overview And Prescribing Guidelines In Depression", <i>South Med J</i> 84(2):222-224 (1991)			
	75	Nelson J.C., "Augmentation Strategies With Serotonergic-Noradrenergic Combinations", <i>J Clin Psychiatry</i> , 59 Suppl 5:65-68 (1998)			
	76	Fatemi <i>et al.</i> , "Venlafaxine And Bupropion Combination Therapy In A Case Of Treatment-Resistant Depression", <i>Ann Pharmacother</i> 33(6):701-703 (1999)			
	77	Marshall <i>et al.</i> , "Paroxetine/Bupropion Combination Treatment For Refractory Depression", <i>J Clin Psychopharmacol</i> , 16:80-81 (1996)			
	78	Pierre <i>et al.</i> , "Bupropion-Tranylcypromine Combination For Treatment-Refractory Depression". <i>J Clin Psychiatry</i> , 61:450-451 (2000)			
	79	Leppik I.E., "Antiepileptic Drugs In Development: Prospects For The Near Future", <i>Epilepsia</i> , 35 Suppl 4:S29-40 (1994)			
	80	May <i>et al.</i> , "Fluctuations Of 10-Hydroxy- Carbazepine During The Day In Epileptic Patients", <i>Acta Neurol Scand</i> 93(6):393-7 (1996)			
	81	Pisani <i>et al.</i> , "Effects Of The Antidepressant Drug Viloxazine On Oxcarbazepine And Its Hydroxylated Metabolites In Patients With Epilepsy", <i>Acta Neurol Scand</i> , 90(2):130-132 (1994)			
	82	Kristensen <i>et al.</i> , "Pharmacokinetics Of 10-OH-Carbazepine, The Main Metabolite Of The Antiepileptic Oxcarbazepine, From Serum And Saliva Concentrations", <i>Acta Neurol Scand</i> , 68(3):145-150 (1983)			
	83	Larkin <i>et al.</i> , "Lack Of Enzyme Induction With Oxcarbazepine (600 mg daily) In Healthy Subjects", <i>Br. J Pharmacol</i> , 31(1):65-71 (1991)			
	84	Zakrzewska <i>et al.</i> , "Oxcarbazepine: A New Drug In The Management Of Intractable Trigeminal Neuralgia", <i>J Neurol Neurosurg Psychiatry</i> , 52(4):472-6 (1989)			
	85	Borasiak <i>et al.</i> , "Hyponatremia Induced By Oxcarbazepine In Children", <i>Epilepsy Res</i> , 30:241-6 (1998)			
	86	Jung <i>et al.</i> , "The Distribution Of 10-Hydroxy Carbazepine In Blood Compartments", <i>Biopharm Drug Dispos</i> 18(1):17-23 (1997)			
	87	Dunkin <i>et al.</i> , "Executive Dysfunction Predicts Nonresponse To Fluoxetine In Major Depression", <i>J Affect Disord</i> , 60(1):13-23 (2000)			
	88	Mayberg <i>et al.</i> , "Regional Metabolic Effects Of Fluoxetine In Major Depression: Serial Changes And Relationship To Clinical Response", <i>Biol Psychiatry</i> 48:830-843 (2000)			
	89	Brown G.M., "Neuroendocrine Probes As Biological Markers Of Affective Disorders: New Directions", <i>Can J Psychiatry</i> , 34:819-23 (1989)			
	90	New <i>et al.</i> , "Serotonin And The Prediction Of Response Time To Fluoxetine In Patients With Mild Depression", <i>Psychiatry Res</i> , 88(2):89-93 (1999)			
	91	Zanardi <i>et al.</i> , "Efficacy Of Paroxetine In Depression Is Influenced By A Functional Polymorphism Within The Promoter Of The Serotonin Transporter Gene", <i>J Clin Psychopharmacol</i> 20:105-107 (2000)			
	92	Cook <i>et al.</i> , "Early changes in prefrontal activity characterize clinical responders to antidepressants," <i>Neuropsychopharmacology</i> , 27(1):120-31 (2002)			
	93	Cook <i>et al.</i> , "Prefrontal Changes And Treatment Response Prediction In Depression". <i>Semin Clin Neuropsychiatry</i> , 6(2):113-20 (2001) [abstract only]			
Examiner:		Date Considered: 7/7/06			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					